EXPOSURE-RESPONSE RELATIONSHIPS FOR EFFICACY AND SAFETY OF FILGOTINIB AND ITS METABOLITE GS-829845 IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY
Amy Meng 1
1 Gilead Sciences, Inc
Topic
Disease Mechanisms, IBD
Session
IBD: Clinical trials poster I
Conference
UEG Week Virtual 2021
Login to access library content
Do you need help setting up your myUEG account?
Contact us at [email protected]
New to myUEG?
Social Sharing